BioLife Solutions, Inc. Stock News

Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash. , Nov. 14, 2024 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ...

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Rod de Greef - Chairman and Chief Executive Officer Garrie Richardson - Chief Revenue Officer Conference Call Participants Matt Stanton - Jefferies Brendan Smith - TD Cowen Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital...

Cell Processing revenue grew 6%  sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51%  and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 mill...

Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash. , Nov. 12, 2024 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its ...

BOTHELL, Wash. , Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024.

BioLife was overextended on acquisitions, leading to margin compression and dilution of shareholder capital. The company has divested from non-core businesses, focusing on preservation media where it is a market leader. Improved financial results include gross margin expansion, lower OpEx, and increased revenue guidance, driven by growth in the Cell Processing business.

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Rod de Greef – Chairman and Chief Executive Officer Garrie Richardson – Chief Revenue Officer Conference Call Participants Jacob Johnson – Stephens Anna Snopkowski – KeyBanc Matt Stanton – Jefferies Steven Mah – TD Cowen Thomas Flaten –...

Cell Processing revenue increased 11%  sequentially to $18.0 million GAAP gross margin of 51%  and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 ...